Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases
- PMID: 20549816
- DOI: 10.1002/cncr.25391
Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases
Abstract
Background: The aim of this study was to assess the role of systemic treatment after whole-brain radiotherapy (WBRT) in immunohistochemically defined biological subsets of breast cancer patients with brain metastases.
Methods: The group of 420 consecutive breast cancer patients with brain metastases treated at the same institution between the years of 2003 to 2009 was analyzed. Patients were divided into 4 immunohistochemically biological subsets, based on the levels of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptors, and labeled as luminal A, luminal B, HER2, and triple-negative. Survival from brain metastases with and without systemic treatment after WBRT was calculated in 4 subsets.
Results: In the entire group, the median survival from brain metastases in patients without and with systemic treatment after WBRT was 3 and 10 months, respectively (P < .0001). In the triple-negative subset, the median survival from brain metastases with and without systemic treatment was 4 and 3 months (P = .16), and in the luminal A subset, it was 12 and 3 months, respectively (P = .003). In the luminal B subset, the median survival without further treatment, after chemotherapy and/or hormonal therapy, and after chemotherapy and/or hormonal therapy with targeted therapy was 2 months, 9 months, and 15 months, respectively (P < .0001). In the HER2 subset, the median survival was 4 months, 6 months, and 13 months, respectively (P < .0001). No significant response to systemic treatment was noted in the triple-negative breast cancer population.
Conclusions: Systemic therapy, ordered after WBRT, appears to improve survival in patients with the luminal A, luminal B, and HER2 breast cancer subtypes. Targeted therapy was found to have an additional positive impact on survival. In patients with triple-negative breast cancer, the role of systemic treatment after WBRT appears to be less clear, and therefore this issue requires further investigation.
© 2010 American Cancer Society.
Similar articles
-
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).Oncology. 2012;83(3):141-50. doi: 10.1159/000338782. Epub 2012 Jul 18. Oncology. 2012. PMID: 22814315
-
Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.Breast Cancer Res Treat. 2011 Jul;128(1):171-7. doi: 10.1007/s10549-011-1526-y. Epub 2011 Apr 26. Breast Cancer Res Treat. 2011. PMID: 21519835
-
Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.Breast Cancer. 2016 Sep;23(5):732-9. doi: 10.1007/s12282-015-0631-x. Epub 2015 Aug 13. Breast Cancer. 2016. PMID: 26267412 Clinical Trial.
-
γ knife radiosurgery of brain metastasis from breast cancer.Prog Neurol Surg. 2012;25:156-62. doi: 10.1159/000331189. Epub 2012 Jan 6. Prog Neurol Surg. 2012. PMID: 22236677 Review.
-
Treatment of brain metastases in patients with HER2+ breast cancer.Adv Ther. 2009 Jul;26 Suppl 1:S18-26. doi: 10.1007/s12325-009-0047-0. Epub 2009 Jul 24. Adv Ther. 2009. PMID: 19669638 Review.
Cited by
-
Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.In Vivo. 2018 Jul-Aug;32(4):839-842. doi: 10.21873/invivo.11317. In Vivo. 2018. PMID: 29936468 Free PMC article.
-
Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.Transl Lung Cancer Res. 2016 Dec;5(6):637-646. doi: 10.21037/tlcr.2016.11.02. Transl Lung Cancer Res. 2016. PMID: 28149758 Free PMC article. Review.
-
Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective.Breast Cancer (Dove Med Press). 2022 Jan 10;14:1-13. doi: 10.2147/BCTT.S274514. eCollection 2022. Breast Cancer (Dove Med Press). 2022. PMID: 35046721 Free PMC article. Review.
-
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Breast Cancer Res Treat. 2018 Oct;171(3):637-648. doi: 10.1007/s10549-018-4852-5. Epub 2018 Jun 25. Breast Cancer Res Treat. 2018. PMID: 29938395 Free PMC article. Clinical Trial.
-
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.Future Oncol. 2019 Jul;15(19):2211-2225. doi: 10.2217/fon-2019-0180. Epub 2019 May 10. Future Oncol. 2019. PMID: 31074641 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous